UNITED THERAPEUTICS Corp
About UNITED THERAPEUTICS Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $3.2B
- Net income
- $1.3B
- Total assets
- $7.9B
- Market cap
- $23.3B
- Gross margin
- 87.9%
- Operating margin
- 46.9%
- Net margin
- 41.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.2B
- Cost of revenue
- $384.4M
- Gross profit
- $2.8B
- Operating expenses
- $1.3B
- Operating income
- $1.5B
- Income tax
- $379.2M
- Net income
- $1.3B
- EPS (basic)
- $30.13
- EPS (diluted)
- $27.86
Balance sheet
- Total assets
- $7.9B
- Current assets
- $3.7B
- Total liabilities
- $783.8M
- Current liabilities
- $560.6M
- Shareholders’ equity
- $7.1B
Cash flow
- Operating cash flow
- $1.6B
- Investing cash flow
- -$551.3M
- Financing cash flow
- -$1.1B
- Net cash flow
- -$140.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $23.3B
- P/E ratio
- 19.5
- EPS (diluted)
- $27.86
- Shares outstanding
- 42.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 17, 1999
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.3B in FY2025.
- Revenue grew 89% from FY2021 to FY2025.
- Gross margin of 87.9%, net margin 41.9%.
- Trading 9% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 19.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review UNITED THERAPEUTICS Corp.
Write a review
News about UNITED THERAPEUTICS Corp
News & sentiment via Polygon.io
